Boston Scientific Proceeds from issuance of common stock relating to employee stock plans increased by 305.0% to $81.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 29.6%, from $115.00M to $81.00M. Over 4 years (FY 2021 to FY 2025), Proceeds from issuance of common stock relating to employee stock plans shows an upward trend with a 26.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Higher proceeds generally correlate with higher employee participation in equity plans and can indicate positive sentiment regarding the company's long-term stock performance.
Cash inflows resulting from the exercise of employee stock options or purchases through employee stock purchase plans. T...
Standard for most publicly traded companies with equity-based compensation programs.
financing_proceeds_from_stock_plans| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $20.00M | $64.00M | $8.00M | $52.00M | $6.00M | $59.00M | $19.00M | $63.00M | $27.00M | $75.00M | $17.00M | $80.00M | $26.00M | $96.00M | $28.00M | $115.00M | $32.00M | $115.00M | $20.00M | $81.00M |
| QoQ Change | — | +220.0% | -87.5% | +550.0% | -88.5% | +883.3% | -67.8% | +231.6% | -57.1% | +177.8% | -77.3% | +370.6% | -67.5% | +269.2% | -70.8% | +310.7% | -72.2% | +259.4% | -82.6% | +305.0% |
| YoY Change | — | — | — | — | -70.0% | -7.8% | +137.5% | +21.2% | +350.0% | +27.1% | -10.5% | +27.0% | -3.7% | +28.0% | +64.7% | +43.8% | +23.1% | +19.8% | -28.6% | -29.6% |